Novel imidazoline derivatives were discovered to be potent neuropeptide Y Y5 receptor antagonists. High-throughput screening of Merck sample collections against the human Y5 receptor resulted in the identification of 2, 4, 4-triphenylimidazoline (1), which had an IC50 of 54nM. Subsequent optimization led to the identification of several potent derivatives.